Lactobacillus plantarum 관련 Irritable Bowel Syndrome (IBS)
BReduces abdominal pain and bloating in IBS. Multiple RCTs show significant improvement in global IBS symptom scores. Strain-specific evidence for 299v is relatively strong.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dplantarum\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
Reduces abdominal pain and bloating in IBS. Multiple RCTs show significant improvement in global IBS symptom scores. Strain-specific evidence for 299v is relatively strong.
Key Study Findings
Meta-Analysis
n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None
vs: placebo
Outcome: quality of life, depression, and anxiety in IBS …
효과: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression)
None
대상 집단: patients with irritable bowel syndrome
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
효과: None
None
대상 집단: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Other
n=25
4 weeks
Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 …
Dose: Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917
vs: phosphate-buffered saline (PBS)
Outcome: visceral hypersensitivity (abdominal withdrawal reflex scores)
효과: None
p<0.05
대상 집단: female rats with water avoidance stress-induced IBS-D model
Other
n=1098
8 weeks
Open-label
A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …
Dose: None
vs: None (single-arm open-label)
Outcome: Treatment success for abdominal pain and bloating
효과: 73% pain, 81.9% bloating success at T1
<0.001
대상 집단: IBS patients from 52 Italian gastroenterologists
Other
Lactobacillus plantarum and Galacto-Oligosaccharides Synbiotic Relieve Irritable Bowel Syndrome by Reshaping Gut Microbiota and Attenuating …
Dose: 1e9 CFU/day + GOS 10 g/L
vs: IBS model mice without synbiotic
Outcome: IBS symptoms and colonic dysfunction
효과: None
<0.05
대상 집단: C. rodentium + WAS IBS mouse model
Randomized Controlled Trial
n=61
12 weeks
Double-blind
Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel …
Dose: None
vs: Placebo
Outcome: IBS-SSS (100-point reduction)
효과: 45% active vs 33% placebo (P=0.42)
P=0.42
대상 집단: IBD patients with IBS symptoms in remission
Key Statistics
5
연구
800
참여자
↑
Positive
B
등급
Referenced Papers
Journal of clinical …
2026
European journal of …
2026
Journal of the …
2026
Nutrients
2025
6 인용
World journal of …
2025
2 인용
Journal of microbiology …
2025
1 인용
Beneficial microbes
2025
Food & function
2024
14 인용
Minerva gastroenterology
2024
4 인용
Journal of neurogastroenterology …
2024
4 인용
Frontiers in medicine
2024
2 인용
Journal of applied …
2024
1 인용
Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.
Meta-Analysis
Gastroenterology
2023
75 인용
Drugs
2023
21 인용
Food & nutrition …
2022
26 인용
Journal of neurogastroenterology …
2022
21 인용
Nutrients
2022
20 인용
Frontiers in nutrition
2022
13 인용
JPMA. The Journal …
2022
6 인용
Beneficial microbes
2021
69 인용
Frontiers in immunology
2021
67 인용
European journal of …
2021
49 인용
Microorganisms
2021
47 인용
Digestive diseases (Basel, …
2021
28 인용
Food & function
2021
21 인용
Frontiers in pain …
2021
15 인용
Przeglad gastroenterologiczny
2021
14 인용
Central-European journal of …
2020
38 인용
The primary care …
2020
32 인용
Nutrition journal
2020
28 인용
European review for …
2020
21 인용
Probiotics and antimicrobial …
2020
21 인용
Probiotics and antimicrobial …
2019
43 인용
Foods (Basel, Switzerland)
2019
21 인용
Acta bio-medica : …
2019
6 인용
Food & function
2018
77 인용
Digestive diseases and …
2018
57 인용
Applied microbiology and …
2015
107 인용
Nutrition (Burbank, Los …
2014
64 인용
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 인용
PloS one
2012
445 인용
World journal of …
2012
277 인용
Journal of clinical …
2012
207 인용
Polski merkuriusz lekarski …
2012
8 인용
Revista espanola de …
2009
1 인용
Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature.
Review
Journal of clinical …
2005
54 인용
Zeitschrift fur Gastroenterologie
2005
17 인용
Journal of clinical …
2004
205 인용
Anaerobe
2004
40 인용
Digestive diseases and …
2002
250 인용
Current treatment options …
2002
5 인용
European journal of …
2001
518 인용
The American journal …
2000
648 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day (299v strain) for 4 weeks minimum
상한량: Well-tolerated up to 20 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | 3154 |
| None | -- | Positive | -- |
| Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 | 4 weeks | Positive | 25 |
| None | 8 weeks | Positive | 1098 |
| 1e9 CFU/day + GOS 10 g/L | -- | Positive | -- |
| None | 12 weeks | Neutral | 61 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
권장 복용 시간: On an empty stomach or before meals
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional loose stools
- ⚠ Histamine-related symptoms in sensitive individuals (histamine-producing species)
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
- ● Histamine-intolerance medications (L. plantarum may produce biogenic amines)
일일 최대 섭취 허용량: Well-tolerated up to 20 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Lactobacillus plantarum help with Irritable Bowel Syndrome (IBS)?
Based on 5 studies with 800 participants, there is moderate evidence from clinical studies that Lactobacillus plantarum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus plantarum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus plantarum?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Histamine-related symptoms in sensitive individuals (histamine-producing species), Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus plantarum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 5 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Irritable Bowel Syndrome (IBS)
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.